Phaseline

Companies › Ageless Biotech

Ageless Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OA-SYS
cell therapy derived from adipose tissue
–Phase 2OsteoarthritisMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06485843OA-SYSPhase 2OsteoarthritisImmunologyMar 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.